Tocilizumab

 Drug class: Monoclonal antibody; IL-6 receptor antagonist.

• Mechanism of action:
  • Binds to soluble and membrane-bound IL-6 receptors (IL-6R).
  • Blocks IL-6 signaling → reduces inflammation, cytokine-driven immune activation.

Indications (FDA/EMA approved):

• Oncology/Cell therapy–related:
  • Cytokine release syndrome (CRS) associated with CAR-T cell therapy (approved in adults and pediatrics ≥2 years).
• Rheumatology/other uses:
  • Rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, systemic sclerosis-associated ILD.
• COVID-19 (emergency use/expanded indications):
  • Severe COVID-19 pneumonia with systemic inflammation.

Dosing (IV only for CRS):

• Adults: 8 mg/kg IV over 60 min (max 800 mg per dose). May repeat every 8 hrs; max 4 doses.
• Children ≥2 years: <30 kg: 12 mg/kg; ≥30 kg: 8 mg/kg IV.

Key adverse effects:

• Infections: Serious bacterial/viral/fungal infections (screen for TB, hepatitis before use in chronic settings).
• Hematologic: Neutropenia, thrombocytopenia.
• Hepatic: Elevated LFTs.
• GI: Rare GI perforation (especially with diverticulitis).
• Infusion-related reactions.

Pharmacist notes (Oncology focus):

• CAR-T therapy setting:
  • First-line treatment for CRS.
  • Often combined with corticosteroids if severe or refractory CRS.
  • Does not impair CAR-T cell efficacy, unlike prolonged high-dose steroids.
• Monitor: CBC, LFTs, signs of infection.
• Vaccination note: Avoid live vaccines during and after therapy.

High-yield for oncology pharmacist / BCOP prep:

• Target: IL-6 receptor.
• Key use: Cytokine release syndrome post–CAR-T.
• Toxicities: Infections, hepatotoxicity, cytopenias, GI perforation.
• Dosing limit: Max 800 mg per infusion; up to 4 doses.